Exclusive Summary

• The unique 0.1g (100mg) low-dose specification perfectly meets the precise titration needs for pediatric fever and geriatric patients, effectively bypassing the red ocean competition of conventional high-dose markets.
• As a WHO Essential Medicine and first-line NSAID, it addresses the evergreen demand of over 500 million arthritis patients globally and billions of episodes of fever and pain, immune to economic cycles.
• Backed by China's absolute dominance in the global Ibuprofen supply chain, the product boasts significant 'API + FDF' integrated cost advantages, making it ideal for overseas distributors targeting OTC retail and public procurement.